Although KRAS mutations are generally unrelated to LNM status or tumor characteristics [4,9], our study demonstrates a shift in KRAS mutation rates across the two LNM-negative subtypes, potentially offering survival benefits to CRC patients with BRAF mutations. This evidence concerns the gene KRAS and neoplasm.